Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kiniksa Pharmaceuticals, Ltd. KNSA
$13.75
-$0.16 (-1.15%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
981389022.00000000
-
week52high
17.20
-
week52low
7.36
-
Revenue
220180000
-
P/E TTM
5
-
Beta
-0.10691100
-
EPS
3.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Buy | Buy | 29 дек 2021 г. |
| B of A Securities | Buy | 01 апр 2020 г. | |
| JP Morgan | Overweight | Overweight | 11 мар 2020 г. |
| Goldman Sachs | Buy | Neutral | 06 дек 2019 г. |
| JMP Securities | Market Outperform | Market Outperform | 14 авг 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Quart Barry D | D | 0 | 21959 | 29 ноя 2022 г. |
| Quart Barry D | D | 0 | 21959 | 29 ноя 2022 г. |
| Quart Barry D | A | 21959 | 21959 | 29 ноя 2022 г. |
| Paolini John F. | D | 169217 | 28357 | 07 ноя 2022 г. |
| Paolini John F. | D | 36335 | 28357 | 07 ноя 2022 г. |
| Paolini John F. | A | 64692 | 28357 | 07 ноя 2022 г. |
| Megna Michael R | D | 525 | 175 | 04 окт 2022 г. |
| Megna Michael R | D | 7414 | 52 | 04 окт 2022 г. |
| Megna Michael R | A | 7466 | 175 | 04 окт 2022 г. |
| Patel Sanj K | D | 19707 | 6569 | 02 сент 2022 г. |
Новостная лента
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 12:32
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Geoff Meacham - Bank of America Operator Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call.
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
GlobeNewsWire
01 мая 2023 г. в 16:01
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution.
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
InvestorPlace
05 апр 2023 г. в 13:40
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.
7 Small-Cap Stocks to Buy for Explosive Growth Potential
InvestorPlace
30 мар 2023 г. в 14:20
While most financial advisors will direct you to a healthy portion of established, large-capitalization enterprises, small-cap stocks to buy provide extra oomph for willing participants. For example, age can be a determining factor in whether smaller, more speculative enterprises are appropriate.
7 Dirt-Cheap Stocks Sitting in the Sweet Spot
InvestorPlace
23 мар 2023 г. в 14:25
While it's always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap where investors might fret about possible value traps. On this list, I'm only going to target (as of the time of writing) equity shares that trade between $10 and $20.